Biotech's Next Big Thing: Fall Trials
Its been a busy summer for biotech, but the coming weeks will heat up with trials from Biodel, Achillon and Coronado, says Adam Feuerstein, Sr. Columnist at TheStreet.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
